Treatment of adult patients with sepsis‐induced coagulopathy and purpura fulminans using a plasma‐derived protein C concentrate (Ceprotin®)

Publisher Website
Google Scholar
Abstract
Background and Objectives  The aim of this study was to document the effects of supplementation with a plasma‐derived protein C concentrate in adult patients with infectious purpura fulminans.Materials and Methods  We report the effect of the administration of a human protein C concentrate (Ceprotin®, Baxter, Vienna, Austria) in eight adult patients with purpura fulminans. Five patients received the concentrate as level‐adjusted continuous infusion (10 U/kg/h, target protein C activity 100%) and three patients received the concentrate as bolus infusions (100 U/kg every 6 h) in addition to standard sepsis therapy. Heparin, fresh‐frozen plasma, antithrombin‐ and fibrinogen concentrates, low‐dose rtPA, and platelet transfusions were given when appropriate.Results  Six patients had overt disseminated intravascular coagulation: platelets, 19 g/l; fibrinogen, 60 mg/dl; antithrombin, 47%; prothrombin time, 32%; activated partial thromboplastin time (APTT), 88 s; d‐dimer, 66 µg/ml; protein C activity, 29% (medians). Five patients had septic shock, six renal failure and four respiratory failure. Patients received between 5000 and 77 000 U of protein C concentrate over 2·5 days (median); the protein C activity increased to 184% (median) and coagulopathy resolved within 3 days in seven of the eight patients. Six patients survived, one died early from fulminant sepsis, and one died after 14 days from candida sepsis.Conclusions  Our data suggest that treatment with a plasma‐derived protein C zymogen concentrate might be a useful support in adult patients with purpura fulminans.